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ABSTRACTStransmission and immunological complications). The present study investi-
gates the intraoperative transfusion requirements in off-pump coronary
artery bypass grafting (OPCABG) and cost implications of blood products and
cell savers in a Background: of limited resources. Prospective data collection
identiﬁed 60 patients undergoing off-pump coronary artery bypass graft
(OPCABG) surgery at EricWilliamsMedical Sciences Complex, Trinidad. Data
relating to these patients (including pre-operative haemoglobin (Hb), graft
number, presence of diabetes, ejection fraction, pre-operative serum creati-
nine, intra-operative blood use and blood loss) and cost values for cell saver
disposablesandbloodpreparationwereobtained.Twentyunits of packed red
bloodcells (pRBCs)weregiven in theatre (to16/60patients; 27%). Transfusion
requirement was signiﬁcantly lower in patients with fewer grafts required,
higherpreoperativeHb level andnon-diabeticpatients. Cell saverdisposables
and one unit of pRBCs were estimated to cost TT$5000 and TT$1700
respectively. Each patient transfused cost TT$2125. The study demonstrates
the ﬁnancial implications of routine cell saver use in OPCABG in a setting of
limited resources. The cost effectiveness of routine cell saver use remains to
be elucidated, but we recommend the selective use of cell savers in patients
who are at a higher risk for transfusion.
ENDOVENOUS LASER THERAPY (EVLT) FOR THE TREATMENT OF LONG
AND SHORT SAPHENOUS VARICOSE VEINS
Dr.Mudugal, Dr.Heffernan, Mr.Zeynali, Mr.Mason, Mr.Jones. Mersey
Foundation School (FY1), United Kingdom
Introduction: Our study has prospectively looked at all patients under-
going this procedure for incompetence of both long and short saphenous
veins in Southport Hospital between 2006 and 2011 to assess efﬁcacy and
effectiveness.
Method: The audit was a prospective study. The data was collected from
2006 to 2011. There were no exclusion criteria: all patients that had the
procedure were included.
Incidence of complications and further procedures needed were
prospectively recorded for all patients who underwent EVLT during this
time. The effects on existing leg ulcers were also recorded.
Results: 1689 patients were included. M:F 537:1152. Median age 59 years
(range 18e97). Complications included numbness (1.1%), phlebitis and
inﬂammation (0.88%), wound complications (0.24%) and neuralgia
(0.059%). No patients developed a DVT. 41% patients had no complications
whatsoever. 15 of 68 leg ulcers healed completely after the procedure. 687of the 926 patients who had residual veins after the procedure went on to
have sclerotherapy.
Conclusion: Our study demonstrated that the EVLT can be safely used for
the treatment of varicose veins caused by venous insufﬁciency in lower
limbs with very low complication rates. This procedure can even be used in
patients with severe comorbidities in order to treat leg ulcers which result
from venous insufﬁciency. The major disadvantage of EVLT is a signiﬁcant
number of patients (40e55%) need sclerotherapy for residual veins
following the procedure.
VARICOCELE EMBOLISATION AT BNHFT: AN AUDIT ON OUTCOMES OVER
6 YEARS
Dr. Sean Mcllhone. Wessex Foundation School, United Kingdom
Background: Varicocele Embolisation (VE) has been performed at BNHFT
for menwith localised symptoms and/or fertility issues. This audit reviews
the long-term effects of VE to facilitatemanagement and consent for future
patients.
Methods: Patient records were found for 79/83 men recorded having VE at
BNHFT (2005e2011). Records were reviewed and patients were contacted
by phone/email/post to assess symptoms and/or fertility issues at their 3-
month follow-up appointment and today. Seventy-seven of these men
were included in the ﬁnal follow up data.
Results: Many subjects were lost to follow-up. Sixteen subjects (21%)
DNA'd and 25 (32%) had no recorded data 3 months post-op. Forty-eight
subjects (62%) were lost to follow-up today (mean time 3.3 years post-op)
Of those who were followed-up: at 3 months, 26 subjects (72%) had
improved or no symptoms whereas 10 (28%) had no change. Today, 27
subjects (93%) had improved or no symptoms. Two (7%) had no change.
Two men (7%) had conﬁrmed varicocele recurrence.
Sixteen men had the procedure for fertility issues. Four (25%) of these men
have since fathered children. Three (19%) had documented sperm
concentration increase post-op.
Conclusion: VE provides symptomatic relief up to 5 years post-op with
low recorded rates of recurrence. A quarter of subjects with previous
fertility issues now have children.
Many subjects were lost to follow-up, making results validity questionable.
This is multifactorial and will be discussed. Consequently, BNHFT is opti-
mising following up patients (via SMS texting/up-to-date email addresses)
so that in future our outcome data are more complete.
